Home Cart Sign in  
Chemical Structure| 184025-19-2 Chemical Structure| 184025-19-2

Structure of Ciproxifan maleate
CAS No.: 184025-19-2

Chemical Structure| 184025-19-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ciproxifan maleate is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

Synonyms: FUB 359 maleate; Ciproxifan (maleate); FUB 359

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ciproxifan maleate

CAS No. :184025-19-2
Formula : C20H22N2O6
M.W : 386.40
SMILES Code : O=C(C1CC1)C2=CC=C(OCCCC3=CNC=N3)C=C2.O=C(O)/C=C\C(O)=O
Synonyms :
FUB 359 maleate; Ciproxifan (maleate); FUB 359
MDL No. :MFCD06411563

Safety of Ciproxifan maleate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H317-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of Ciproxifan maleate

GPCR

Isoform Comparison

Biological Activity

Description
iproxifan maleate (FUB 359 maleate) is a potent, selective, orally bioavailable, and competitive antagonist of the histamine H3 receptor, demonstrating an IC50 of 9.2 nM. It exhibits low apparent affinity at other receptor subtypes and is applicable for research into aging disorders and Alzheimer's disease [1][3].
Target
  • H3 receptor

    Histamine H3 receptor, IC50:9.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 10–80μM 48 h Inhibited cell growth and induced apoptosis PMC8285495
H460 cells 10–80μM 48 h Inhibited cell growth and induced apoptosis PMC8285495
H1975 cells 10–80μM 48 h Inhibited cell growth and induced apoptosis PMC8285495

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice H1975 cell xenograft model Intraperitoneal injection 3 mg/kg Every other day Significantly inhibited tumor growth PMC8285495
Mice H1R knockout mice Intraperitoneal injection 0.3, 1, or 3 mg/kg Single dose, observed for 24 hours To investigate the effect of the H3R antagonist ciproxifan on wakefulness in WT and H1R KO mice. Results showed that ciproxifan dose-dependently increased wakefulness in WT mice but had no effect in H1R KO mice. PMC1450232
Rat Gastric mucosal injury model Intragastric administration 3 mg/kg Single dose, administered 30 minutes prior To investigate the effect of Ciproxifan on (R)-α-methylhistamine-induced gastric mucosal cell proliferation and migration. Results showed that Ciproxifan reversed the (R)-α-methylhistamine-induced proliferation and accelerated migration. PMC1573479
Rat HCl-induced gastric mucosal lesion model Intragastric administration 0.3, 1 and 3 mg/kg Single dose, 30 minutes before (R)-a-methylhistamine, followed by HCl 30 minutes later To investigate the inhibitory effect of ciproxifan on the gastroprotective action of (R)-a-methylhistamine. Results showed that ciproxifan dose-dependently inhibited the protection exerted by (R)-a-methylhistamine, with the highest dose almost completely reversing the protective effect. PMC1572006
Mice H3R knockout mice and wild-type C57BL/6J mice Intraperitoneal injection 0.3, 1, or 3 mg/kg Single administration, 30 minutes before DID experiment To investigate the effect of H3R antagonist ciproxifan on alcohol intake in mice. Results showed that ciproxifan significantly reduced alcohol consumption but had no effect on sucrose intake. PMC3158320
Mice C57Bl/6J male mice Intraperitoneal injection 3 mg/kg Single dose, 30 minutes before testing To investigate the effects of ciproxifan on contextual memory retrieval in mice under stress and non-stress conditions. Results showed that ciproxifan enhanced memory retrieval of D2 in non-stress condition and of D1 in stress condition. Additionally, ciproxifan mitigated the stress-induced increase in Fos expression in the prelimbic and infralimbic cortex, central and basolateral amygdala, and the CA1 region of the dorsal hippocampus. PMC6630007
Adult male Long-Evans rats MK-801-induced behavioral dysfunction model Subcutaneous injection 1.0 and 3.0 mg/kg Single administration, 20 minutes before testing Ciproxifan enhanced the effects of MK-801 on locomotor activity and ataxia, but did not alter the changes in auditory startle and PPI induced by MK-801. Additionally, ciproxifan alleviated the impairment of delayed spatial alternation caused by MK-801. PMC2946466

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.94mL

2.59mL

1.29mL

25.88mL

5.18mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories